//Imperial Brands Science at CORESTA 2021

IMPERIAL BRANDS IS PRESENTING A NUMBER OF EXCITING RESEARCH PROJECTS AT THIS YEAR’S CORESTA CONGRESS AS PART OF OUR ONGOING SCIENTIFIC SUBSTANTIATION OF OUR NEXT GENERATION PRODUCT PORTFOLIO…

CORESTA (Cooperation Centre for Scientific Research Relative to Tobacco) promotes international cooperation in scientific research relating to tobacco and Next Generation Products (NGPs).

As a longstanding member of the association, Imperial Brands traditionally presents at CORESTA’s annual congresses – where we share our latest research, invite feedback and continue to enhance the scientific understanding of NGPs to best serve our adult smoker consumers.

This year is no different, with an extensive list of presentations at October 2021’s Smoke Science & Product Technology (SSPT) Virtual Conference.

This year, we’re presenting around perceptions and behaviours relating to tobacco-free oral nicotine pouch products. We’re also sharing population health research which models the effects of introducing NGPs into a market and the ensuing impact on smoking prevalence.

There’s novel in-vitro data demonstrating the harm reduction potential of our heated tobacco device Pulze, plus encouraging recently published clinical data relating to our vape product myblu which demonstrates rapid and significant reductions in select disease-related biomarkers of exposure to harmful chemicals when adult smokers either fully or partially transition to vaping, as well as dramatic reversals of these results if smoking is resumed.

For the full itinerary of Imperial Brands Science’s input in the SSPT at CORESTA, please see below.

MONDAY 18 OCTOBER: SESSION 1

Perception and behaviour: understanding how nicotine products are perceived and used

ST04 – Risk perceptions and likelihood of use of (tobacco-free oral) nicotine pouches among current, former and never nicotine users. STONE C.; KNIGHT-WEST O.; O’CONNELL G.; TOPE A

ST05 – Assessing the impact of next generation products on population health: a population modelling approach. PHILLIPS C.V.; KHAKWANI A.; O’CONNELL G.; CAHOURS X.; TOPE A.

WEDNESDAY 20 OCTOBER: SESSION 2

Heated tobacco products: methods

ST19 – Substantial reductions in selected harmful or potentially harmful constituents in heated tobacco aerosol, compared to 1R6F reference cigarette smoke, correlated with substantially reduced in vitro toxicological outcomes. CHAPMAN F.; TRELLES STICKEN E.; WIECZOREK R.; POUR S.J.; DETHLOFF O.; STEVENSON M.

TUESDAY 26 OCTOBER: SESSION 1

Biomarkers in clinical science: human data for assessing tobacco harm reduction

ST46 – Reductions in biomarkers of exposure to selected harmful and potentially harmful constituents following complete or partial transition to myblu™ ENDS (exclusive or dual use) compared to continued combustible cigarette smoking MORRIS P.; McDERMOTT S.; CHAPMAN F.; VERRON T.; CAHOURS X.; STEVENSON M.; THOMPSON J.; CHAUDHARY N.; O’CONNELL G.

TUESDAY 26 OCTOBER: SESSION 2

Toxicological assessment: nonclinical toxicity assessment of nicotine products

ST49 – Assessment of alternative cell lines for adoption within the OECD TG 129 for cytotoxicity determination POUR S.J.; WIECZOREK R.; CZEKALA L.

THURSDAY 28 OCTOBER SESSION 2

Statistics and laboratory operations

ST 69 – A robust statistical approach for estimating method precision GUO M.; VERRON T.; CAHOURS X

All materials will be made available both here and in the science website research archive following their presentation at CORESTA.